G-Benzosal6%+3%

G-Benzosal is a topical antifungal-keratolytic combination indicated for the treatment of superficial fungal (dermatophyte) infections of the skin.

Established/traditional uses

• Tinea pedis (athlete's foot)
• Tinea corporis (ringworm of the body)
• Tinea cruris (jock itch)
• Other superficial dermatophytoses with associated scaling/hyperkeratosis where a combined keratolytic-antifungal action is appropriate

G-Benzosal works by combining a mild topical antifungal (benzoic acid) with a keratolytic agent (salicylic acid) that helps soften and remove thickened, scaly skin, improving penetration of the antifungal component. Evidence for this combination comes from long-standing clinical and pharmacopoeial use (classically known as Whitfield's ointment) rather than large modern randomized trials, so it is generally regarded as a low-cost, first-line option for mild, uncomplicated superficial fungal skin infections rather than a substitute for prescription antifungals in extensive, resistant, or nail/scalp infections.

Benzoic Acid + Salicylic Acid is a fixed-dose topical combination of two active ingredients, typically formulated in an ointment or cream base (e.g., petrolatum or emulsifying base):

• Benzoic acid — usually 6% w/w (strong formulation) or 3% w/w (mild formulation)
• Salicylic acid — usually 3% w/w (strong formulation) or 1.5% w/w (mild formulation)

The exact strength may vary slightly between manufacturers; the strong formulation is generally used on thicker-skinned areas (e.g., soles), and the mild formulation on thinner-skinned or sensitive areas (e.g., groin, face-adjacent skin), as directed by a physician.

G-Benzosal is a topical combination product classically known as Whitfield's ointment, used for decades in the management of superficial fungal skin infections. It combines a weak antifungal/antiseptic agent (benzoic acid) with a keratolytic agent (salicylic acid) that helps shed the outer, infected layer of skin and enhances penetration of the antifungal component.

It is applied externally to the skin only and is not intended for oral, ophthalmic, or mucosal use. It remains a widely available, inexpensive option for mild dermatophyte infections, particularly in resource-limited settings.

G-Benzosal belongs to the therapeutic class of topical antifungal and keratolytic combination agents, used in dermatology for superficial fungal skin infections.

Benzoic Acid + Salicylic Acid combines two agents with complementary actions:

• Salicylic acid is a keratolytic agent. It lowers the pH of the stratum corneum and disrupts intercellular cohesion between keratinocytes, causing softening and desquamation of thickened, scaly, infected skin. This mechanically reduces the fungal load and improves penetration of the antifungal component into deeper layers of the epidermis.
• Benzoic acid is a weak, fungistatic antimicrobial agent. In its undissociated form, it penetrates the fungal cell wall and interferes with fungal cellular metabolism (including inhibition of enzyme systems involved in fungal respiration), thereby inhibiting the growth of dermatophytes. Its activity is enhanced by the acidic environment produced by salicylic acid.

Together, Benzoic Acid + Salicylic Acid provides a combined keratolytic and mild antifungal effect useful for uncomplicated superficial dermatophyte infections.

• Wash and dry the affected area thoroughly before applying G-Benzosal.
• Apply a thin, even layer over the affected skin and a small margin of surrounding normal skin.
• Gently rub in until absorbed; avoid occlusive dressings unless directed by a physician.
• Wash hands thoroughly after application, unless the hands are the treated area.
• Avoid contact with the eyes, lips, mouth, and other mucous membranes.
• Do not apply to broken, cracked, weeping, or acutely inflamed skin.
• Do not cover treated skin tightly or apply over a larger area than directed, as this increases systemic absorption.

When G-Benzosal is used topically on limited areas of intact skin as directed, systemic absorption is minimal and clinically significant drug interactions are uncommon.

• Other topical keratolytics/irritants (e.g., other salicylic acid–containing products, benzoyl peroxide, retinoids, or strong exfoliants): concurrent use on the same area may have an additive irritant effect; avoid combining unless advised by a physician.
• Systemic salicylates (e.g., oral aspirin) in patients using large amounts of G-Benzosal over extensive skin areas: theoretical additive risk of salicylate toxicity due to combined systemic exposure; use with caution.

Most side effects of G-Benzosal are local and mild:

• Transient burning or stinging sensation on application
• Local skin irritation, redness, or dryness
• Peeling or scaling of treated skin (an expected keratolytic effect)
• Contact dermatitis or allergic skin reaction (uncommon)

Rare/serious: With excessive application, use over large body surface areas, prolonged use, or use under occlusion — particularly in infants and children — systemic absorption of salicylate can occur, leading to salicylism (salicylate toxicity), with symptoms such as tinnitus, hyperventilation, nausea, vomiting, dizziness, confusion, or, rarely, metabolic disturbances. Discontinue use and seek medical attention if such symptoms occur (see Overdose Effects).

There are limited controlled data on the use of G-Benzosal during pregnancy and breastfeeding. Topical application to small, limited areas of intact skin as directed is expected to result in minimal systemic absorption; however, G-Benzosal should be used during pregnancy and lactation only if clearly needed, at the lowest effective area/duration, and only after the potential benefit is judged by a physician to outweigh any potential risk to the fetus or nursing infant.

Avoid application to large areas or for prolonged periods during pregnancy and lactation due to the theoretical risk of increased systemic salicylate absorption. Consult a physician before use in pregnancy or while breastfeeding.

• G-Benzosal is for external use only; avoid contact with the eyes, mouth, mucous membranes, and open wounds.
• Do not apply to broken, cracked, weeping, or acutely inflamed skin.
• Avoid application over large body surface areas or for prolonged, continuous periods without medical supervision, due to the risk of systemic salicylate absorption (salicylism), which is of particular concern in infants, young children, and patients with renal or hepatic impairment.
• Discontinue use and consult a physician if excessive irritation, redness, swelling, or signs of allergic reaction develop.
• Avoid use on the face, groin, or other thin-skinned/sensitive areas unless a lower-strength (mild) formulation is used, or as directed by a physician.
• Do not use as a substitute for prescription antifungal therapy in extensive, nail (onychomycosis), or scalp (tinea capitis) fungal infections, which require systemic treatment.
• If symptoms do not improve within 2–4 weeks or worsen, seek medical advice, as an alternative diagnosis or resistant infection may need to be considered.
• May stain or bleach clothing and fabric; allow the treated area to dry before dressing.

Overdose with G-Benzosal is unlikely with normal topical use on small areas, but can occur with excessive application, use over large body surface areas, prolonged/occlusive use, or accidental ingestion.

• Excessive topical use/absorption: may cause salicylate toxicity (salicylism), with symptoms such as ringing in the ears (tinnitus), rapid or deep breathing, nausea, vomiting, headache, dizziness, confusion, or drowsiness.
• Accidental ingestion: can cause more severe salicylate toxicity, including vomiting, hyperventilation, metabolic acidosis, seizures, or altered consciousness.

If overdose, accidental ingestion, or signs of salicylate toxicity are suspected, stop use immediately and seek emergency medical attention or contact a poison control center right away. Do not attempt home treatment for suspected systemic toxicity.

Store at room temperature (below 30°C), protected from light and moisture. Keep the container tightly closed. Keep out of reach of children.

Pediatric patients

Use of G-Benzosal in infants and young children should be avoided unless specifically directed by a physician, and then only sparingly on a limited area. Children have a higher body-surface-area-to-weight ratio and thinner skin, which increases percutaneous absorption of salicylate and the risk of salicylism compared with adults. Safety and efficacy of routine use in infants have not been well established.

Elderly patients

No specific dose adjustment is established; apply as directed, monitoring for local skin irritation, as elderly patients may have thinner or more fragile skin.

Renal or hepatic impairment

Topical use as directed on limited areas does not require specific dose adjustment; however, extensive or prolonged application should be avoided, as impaired clearance of absorbed salicylate could theoretically increase the risk of systemic toxicity.

Treatment with G-Benzosal is typically continued for 2 to 4 weeks, or as directed by a physician, and generally for a few additional days after visible skin lesions have resolved to reduce the risk of recurrence. If there is no improvement within 2–4 weeks, or if symptoms worsen, a physician should be consulted to reassess the diagnosis and treatment.

Topical antifungal agent; Keratolytic agent (topical dermatological combination)

Benzoic Acid + Salicylic Acid acts through two complementary mechanisms: salicylic acid produces a keratolytic effect by softening and loosening the outer keratin layer of the skin, promoting shedding of infected, scaly tissue and enhancing drug penetration; benzoic acid provides a mild fungistatic antimicrobial effect by disrupting fungal cell metabolism, an effect enhanced by the acidic environment created by salicylic acid.

The safety and efficacy of G-Benzosal for routine use in infants and young children have not been well established. Because children have a greater body-surface-area-to-body-weight ratio and thinner skin than adults, they are at increased risk of percutaneous salicylate absorption and salicylate toxicity (salicylism) with excessive or prolonged use. If use in a child is considered necessary, it should be done only under the direction of a physician, applied sparingly to the smallest area needed, for the shortest effective duration, and the child should be monitored for any signs of irritation or systemic toxicity.